Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Özlem Türeci
Age : 54
Country of residence : Unknown
Linked companies : BioNTech SE

Biography of Özlem Türeci 
Özlem Türeci founded BioNTech SE and Ganymed Pharmaceuticals AG. Currently, she holds the position of Chairman for Ci3 Management UG, President at Association For Cancer Immunotherapy and Chief Medical Officer for BioNTech SE. In the past she occupied the position of Chief Executive & Medical Officer at Ganymed Pharmaceuticals AG. Dr. Türeci received an undergraduate degree from Universität des Saarlandes.


Current positions of Özlem Türeci 
Özlem Türeci : Personal Network 
Most Read News 
01/18ELON MUSK : Tesla investors urge judge to order Musk repay $13 billion for SolarCity deal
RE
01/11JAMIE DIMON : JPMorgan's Dimon says consumer loan growth may take 6-9 months to return to normal
RE
01/13JACK DORSEY : Jack Dorsey's Block to build an open bitcoin mining system
RE
01/14ELON MUSK : Musk says Tesla to accept dogecoin for merchandise
RE
01/20ALAN JOPE : Unilever strategy under scrutiny after short-lived GSK skirmish
RE
01/10BRUNELLO CUCINELLI : Luxury group Cucinelli posts 31% sales jump in 2021
RE
01/11CATHIE WOOD : ARK's Wood turns focus to deflation, 'stay connected' stocks
RE
01/12MARTIN SORRELL : Sorrell's S4 says trading well ahead of guidance
RE
01/13AMANCIO ORTEGA : Inditex founder Amancio Ortega buys Toronto's Royal Bank Plaza for $916 mln
RE
01/17ELON MUSK : Top Energy News of the Day
DJ
More news


© 2022 People and Ownership :   
Özlem Türeci : Connections 


Latest news about Özlem Türeci 
2021BioNTech CEO says vaccine upgrade on the cards, ready to move quickly
RE
2021REUTERS NEXT-BioNTech CEO says vaccine upgrade on the cards, ready to move quickly
RE
2021PRESS RELEASE : BioNTech to Present New Clinical Data from First-in-Class CAR-T Program BNT211 in Late-breaking Session at 36th SITC Annual Meeting
DJ
2021PRESS RELEASE : FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years
DJ
2021PRESS RELEASE : BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting
DJ
2021PRESS RELEASE : BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients
DJ
2021PRESS RELEASE : FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY(R) Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations
DJ
More news